Dickmeyer Boyce Financial Management Inc. Buys New Stake in CVS Health Corporation $CVS

Dickmeyer Boyce Financial Management Inc. purchased a new stake in shares of CVS Health Corporation (NYSE:CVS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 5,172 shares of the pharmacy operator’s stock, valued at approximately $371,000.

A number of other large investors have also modified their holdings of the company. Swiss RE Ltd. purchased a new stake in shares of CVS Health during the 4th quarter worth about $26,000. Sankala Group LLC purchased a new position in shares of CVS Health in the 4th quarter valued at about $28,000. Caitong International Asset Management Co. Ltd raised its holdings in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the period. Mcguire Capital Advisors Inc. purchased a new position in CVS Health during the fourth quarter worth approximately $28,000. Finally, Ares Financial Consulting LLC acquired a new stake in CVS Health in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts and market commentary pointed to improving execution, stronger payer margins, and a modest lift in CVS’s fair value estimate, suggesting Wall Street sees more upside in the stock. CVS Health (CVS) Stock Sees Modest Fair Value Lift As Analysts Raise Targets
• Positive Sentiment: Options activity was unusually strong, with traders buying far more call options than normal, which can signal expectations for continued upside.
• Positive Sentiment: CVS’s new nationwide pet-prescription service has generated widespread coverage and could support pharmacy traffic and customer engagement. CVS is making it easier for pet owners with a new perk
• Neutral Sentiment: Brokerage coverage remains constructive, with CVS receiving a consensus “Moderate Buy” rating and another recent upgrade to Buy, reinforcing a generally favorable analyst stance. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Several articles highlighted CVS’s community-health investments in Massachusetts, but these are more reputational than immediately material to earnings. CVS Health Helping to Strengthen Communities Across Massachusetts
• Negative Sentiment: Henry Ford Health filed a lawsuit against CVS alleging a 340B pricing scheme, which could create legal and reputational risk if the claims gain traction. Henry Ford Health sues CVS, alleges 340B pricing scheme

Insider Transactions at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,441,551 shares of company stock worth $323,703,977 over the last ninety days. 0.85% of the stock is owned by insiders.

CVS Health Price Performance

NYSE:CVS opened at $106.86 on Friday. CVS Health Corporation has a one year low of $58.50 and a one year high of $110.68. The stock has a market cap of $136.35 billion, a PE ratio of 47.08, a P/E/G ratio of 1.06 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a 50 day moving average price of $99.98 and a 200 day moving average price of $85.97.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the previous year, the company posted $2.25 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts expect that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CVS. Cantor Fitzgerald lifted their target price on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Argus lifted their price objective on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday. Wells Fargo & Company raised their target price on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Finally, Mizuho boosted their price target on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.38.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.